GlassScriptPhysician profile
Suzanne R Olive
NPI 1679532170
$1,413.49
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $258.75 | 2019 | |
| Glaxosmithkline, LLC. | $239.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.93 | 2019 | |
| Grifols USA, LLC | $145.77 | 2019 | |
| Alk-Abello, INC | $121.69 | 2019 | |
| Mylan Specialty L.P. | $108.38 | 2019 | |
| Genentech USA, INC. | $97.49 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $60.13 | 2019 | |
| Jazz Pharmaceuticals INC. | $45.40 | 2019 | |
| Optinose US, INC. | $35.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.89 | 2019 | |
| Shire North American Group INC | $31.93 | 2019 | |
| Insmed, INC. | $30.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.92 | 2019 | |
| Advanced Respiratory, INC | $18.03 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $14.83 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Olive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.